NCT03642067View on ClinicalTrials.gov

Study of Nivolumab and Relatlimab in Patients With Microsatellite Stable (MSS) Advanced Colorectal Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

59

Participants

Timeline

Start Date

February 12, 2019

Primary Completion Date

February 23, 2024

Study Completion Date

September 18, 2024

Conditions
Microsatellite Stable (MSS) Colorectal AdenocarcinomasColorectal Adenocarcinoma
Interventions
DRUG

Nivolumab

Nivolumab was administered IV on day 1 of each 28 day cycle.

DRUG

Relatlimab

Relatlimab was administered IV on day 1 of each 28 day cycle.

Trial Locations (1)

21231

Sidney Kimmel Comprehensive Cancer Center, Baltimore

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER